AB Corporate Bond ETF (NASDAQ:EYEG) Stock Price Passes Below 200-Day Moving Average – Should You Sell?

AB Corporate Bond ETF (NASDAQ:EYEG)’s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $35.33 and traded as low as $34.56. AB Corporate Bond ETF shares last traded at $34.56, with a volume of 1,723 shares traded.

AB Corporate Bond ETF Stock Performance

The company has a fifty day moving average of $35.03 and a two-hundred day moving average of $35.33. The stock has a market capitalization of $27.65 million, a P/E ratio of -20.57 and a beta of 0.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07.

AB Corporate Bond ETF Increases Dividend

The company also recently disclosed a monthly dividend, which was paid on Thursday, August 6th. Investors of record on Monday, August 3rd were paid a dividend of $0.1427 per share. This represents a c) annualized dividend and a yield of 5.0%. This is a boost from AB Corporate Bond ETF’s previous monthly dividend of $0.14. The ex-dividend date was Monday, August 3rd. AB Corporate Bond ETF’s dividend payout ratio (DPR) is -102.38%.

Institutional Trading of AB Corporate Bond ETF

A hedge fund recently bought a new stake in AB Corporate Bond ETF stock. Kestra Advisory Services LLC bought a new position in shares of AB Corporate Bond ETF (NASDAQ:EYEG) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned 0.13% of AB Corporate Bond ETF as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 64.16% of the company’s stock.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.